BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16759919)

  • 1. The spectrum of androgen excess disorders.
    Carmina E
    Fertil Steril; 2006 Jun; 85(6):1582-5. PubMed ID: 16759919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogenic ovulatory dysfunction or functional female hyperandrogenism: an argument to discard the term polycystic ovary syndrome.
    Behera M; Price T; Walmer D
    Fertil Steril; 2006 Nov; 86(5):1292-5. PubMed ID: 17070182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes.
    Guastella E; Longo RA; Carmina E
    Fertil Steril; 2010 Nov; 94(6):2197-201. PubMed ID: 20303485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome.
    Carmina E; Azziz R
    Fertil Steril; 2006 Jul; 86 Suppl 1():S7-8. PubMed ID: 16798288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mild androgen phenotypes.
    Carmina E
    Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):207-20. PubMed ID: 16772152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current diagnosis of polycystic ovary syndrome: expanding the phenotype but generating new questions].
    Merino P; Schulin-Zeuthen C; Codner E
    Rev Med Chil; 2009 Aug; 137(8):1071-80. PubMed ID: 19915773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgens and polycystic ovary syndrome.
    Nisenblat V; Norman RJ
    Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):224-31. PubMed ID: 19390322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of polycystic ovary syndrome.
    Trivax B; Azziz R
    Clin Obstet Gynecol; 2007 Mar; 50(1):168-77. PubMed ID: 17304034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.
    Carmina E; Rosato F; Jannì A; Rizzo M; Longo RA
    J Clin Endocrinol Metab; 2006 Jan; 91(1):2-6. PubMed ID: 16263820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome.
    Goodarzi MO; Azziz R
    Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):193-205. PubMed ID: 16772151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels.
    Fruzzetti F; Perini D; Lazzarini V; Parrini D; Genazzani AR
    Fertil Steril; 2009 Aug; 92(2):626-34. PubMed ID: 18706545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?
    Abbott DH; Barnett DK; Bruns CM; Dumesic DA
    Hum Reprod Update; 2005; 11(4):357-74. PubMed ID: 15941725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary forms of polycystic ovary syndrome.
    Kaltsas GA; Isidori AM; Besser GM; Grossman AB
    Trends Endocrinol Metab; 2004 Jul; 15(5):204-10. PubMed ID: 15223049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shorter CAG repeats in the androgen receptor gene may enhance hyperandrogenicity in polycystic ovary syndrome.
    Van Nieuwerburgh F; Stoop D; Cabri P; Dhont M; Deforce D; De Sutter P
    Gynecol Endocrinol; 2008 Dec; 24(12):669-73. PubMed ID: 19172534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors.
    Sanchón R; Gambineri A; Alpañés M; Martínez-García MÁ; Pasquali R; Escobar-Morreale HF
    Hum Reprod; 2012 Apr; 27(4):1209-16. PubMed ID: 22343706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatology of androgen-related disorders.
    Essah PA; Wickham EP; Nunley JR; Nestler JE
    Clin Dermatol; 2006; 24(4):289-98. PubMed ID: 16828411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia.
    Cho LW; Kilpatrick ES; Jayagopal V; Diver MJ; Atkin SL
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):390-4. PubMed ID: 17888022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome.
    Rachoń D
    Exp Clin Endocrinol Diabetes; 2012 Apr; 120(4):205-9. PubMed ID: 22421986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgens in polycystic ovary syndrome: the role of exercise and diet.
    Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
    Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.